FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2875246115> ?p ?o ?g. }

• W2875246115 endingPage "281" @default.
• W2875246115 startingPage "274" @default.
• W2875246115 abstract "Prostate-specific membrane antigen (PSMA)-based radiopeptide/radioligand therapy represents a rapidly expanding field in the management of metastatic castrate-resistant prostate cancer (mCRPC). However, there remains concern for the development of significant toxicities in heavily pretreated patients. In this study, the authors present their local experience, with respect to efficacy and toxicity, of 22 consecutive patients treated with lutetium-177-DOTAGA-(I-y)fk(Sub-KuE) or 177Lu-PSMA I&T radioimmunotherapy for progressive mCRPC, followed up over 1 year.All patients had progressive mCRPC, an European Cooperative Oncology Group (ECOG) ≤2 with adequate bone marrow and liver function. 177Lu-PSMA I&T therapy was administered at 8-week intervals with a mean prescribed activity of 5.5 GBq (gigabecquerel) per patient.Twenty patients had evaluable results, median age of 71 years, and median duration of follow-up of 17 months. Three patients (15%) experienced a G1/2 myelotoxicity and four (20%) G3/4. No incidences of myelodysplasia/acute leukemia have been identified. All toxicities were self-limiting. Baseline cytopenia was predictive of the development of subsequent G3/4 myelotoxicity (p = 0.0035). Eight patients (40%) experienced an objective PSA response, with a median time to response of 15 weeks. The median time to PSA progression was not reached. Patients receiving three cycles of therapy were statistically more likely to experience a disease response when compared to those treated with one, two, or four cycles (p < 0.0001).177Lu-PSMA I&T radioimmunotherapy of progressive mCRPC is safe and effective with three cycles being the potential optimal number for determining long-term disease response." @default.
• W2875246115 created "2018-07-19" @default.
• W2875246115 creator A5004493560 @default.
• W2875246115 creator A5035741134 @default.
• W2875246115 creator A5050960969 @default.
• W2875246115 creator A5062657203 @default.
• W2875246115 creator A5086752045 @default.
• W2875246115 creator A5087935247 @default.
• W2875246115 date "2018-09-01" @default.
• W2875246115 modified "2023-10-06" @default.
• W2875246115 title "Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine Practice" @default.
• W2875246115 cites W1575816236 @default.
• W2875246115 cites W1757407923 @default.
• W2875246115 cites W1785893016 @default.
• W2875246115 cites W1977316337 @default.
• W2875246115 cites W2014999922 @default.
• W2875246115 cites W2038397362 @default.
• W2875246115 cites W2053716263 @default.
• W2875246115 cites W2087044034 @default.
• W2875246115 cites W2088438005 @default.
• W2875246115 cites W2101265600 @default.
• W2875246115 cites W2105337740 @default.
• W2875246115 cites W2132315278 @default.
• W2875246115 cites W2150402649 @default.
• W2875246115 cites W2155679349 @default.
• W2875246115 cites W2155847415 @default.
• W2875246115 cites W2167331614 @default.
• W2875246115 cites W2229603522 @default.
• W2875246115 cites W2240315679 @default.
• W2875246115 cites W2303817381 @default.
• W2875246115 cites W2345023278 @default.
• W2875246115 cites W2403516958 @default.
• W2875246115 cites W2469875234 @default.
• W2875246115 cites W2501712293 @default.
• W2875246115 cites W2525124727 @default.
• W2875246115 cites W2532226140 @default.
• W2875246115 cites W2590799879 @default.
• W2875246115 cites W2599305587 @default.
• W2875246115 cites W2606187374 @default.
• W2875246115 cites W2609771428 @default.
• W2875246115 cites W2612014481 @default.
• W2875246115 cites W2673309218 @default.
• W2875246115 cites W2754366791 @default.
• W2875246115 cites W2756428015 @default.
• W2875246115 cites W2771847508 @default.
• W2875246115 cites W4205145397 @default.
• W2875246115 doi "https://doi.org/10.1089/cbr.2017.2403" @default.
• W2875246115 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29989440" @default.
• W2875246115 hasPublicationYear "2018" @default.
• W2875246115 type Work @default.
• W2875246115 sameAs 2875246115 @default.
• W2875246115 citedByCount "22" @default.
• W2875246115 countsByYear W28752461152018 @default.
• W2875246115 countsByYear W28752461152019 @default.
• W2875246115 countsByYear W28752461152020 @default.
• W2875246115 countsByYear W28752461152021 @default.
• W2875246115 countsByYear W28752461152022 @default.
• W2875246115 countsByYear W28752461152023 @default.
• W2875246115 crossrefType "journal-article" @default.
• W2875246115 hasAuthorship W2875246115A5004493560 @default.
• W2875246115 hasAuthorship W2875246115A5035741134 @default.
• W2875246115 hasAuthorship W2875246115A5050960969 @default.
• W2875246115 hasAuthorship W2875246115A5062657203 @default.
• W2875246115 hasAuthorship W2875246115A5086752045 @default.
• W2875246115 hasAuthorship W2875246115A5087935247 @default.
• W2875246115 hasConcept C121608353 @default.
• W2875246115 hasConcept C126322002 @default.
• W2875246115 hasConcept C126894567 @default.
• W2875246115 hasConcept C143998085 @default.
• W2875246115 hasConcept C159654299 @default.
• W2875246115 hasConcept C203014093 @default.
• W2875246115 hasConcept C2776146153 @default.
• W2875246115 hasConcept C2776694085 @default.
• W2875246115 hasConcept C2778822529 @default.
• W2875246115 hasConcept C2780007613 @default.
• W2875246115 hasConcept C2780192828 @default.
• W2875246115 hasConcept C2781406297 @default.
• W2875246115 hasConcept C29730261 @default.
• W2875246115 hasConcept C542903549 @default.
• W2875246115 hasConcept C71924100 @default.
• W2875246115 hasConceptScore W2875246115C121608353 @default.
• W2875246115 hasConceptScore W2875246115C126322002 @default.
• W2875246115 hasConceptScore W2875246115C126894567 @default.
• W2875246115 hasConceptScore W2875246115C143998085 @default.
• W2875246115 hasConceptScore W2875246115C159654299 @default.
• W2875246115 hasConceptScore W2875246115C203014093 @default.
• W2875246115 hasConceptScore W2875246115C2776146153 @default.
• W2875246115 hasConceptScore W2875246115C2776694085 @default.
• W2875246115 hasConceptScore W2875246115C2778822529 @default.
• W2875246115 hasConceptScore W2875246115C2780007613 @default.
• W2875246115 hasConceptScore W2875246115C2780192828 @default.
• W2875246115 hasConceptScore W2875246115C2781406297 @default.
• W2875246115 hasConceptScore W2875246115C29730261 @default.
• W2875246115 hasConceptScore W2875246115C542903549 @default.
• W2875246115 hasConceptScore W2875246115C71924100 @default.
• W2875246115 hasIssue "7" @default.
• W2875246115 hasLocation W28752461151 @default.
• W2875246115 hasLocation W28752461152 @default.

• next